Skip to main content
. Author manuscript; available in PMC: 2015 Sep 26.
Published in final edited form as: N Engl J Med. 2015 Feb 18;372(13):1193–1203. doi: 10.1056/NEJMoa1414264

Figure 2. Mean Change in Central Subfield Thickness over Time.

Figure 2

Shown are the changes in central subfield thickness overall (Panel A) and according to baseline visual acuity (Panel B). In Panel B, solid lines indicate baseline visual acuity of 20/50 or worse, and dashed lines indicate baseline visual acuity of 20/32 to 20/40. Central subfield thickness was assessed with the use of optical coherence tomography. The number of eyes assessed at each 4-week interval ranged from 192 to 221 in the aflibercept group, 186 to 216 in the bevacizumab group, and 185 to 215 in the ranibizumab group. I bars indicate 95% confidence intervals.